Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a ...

Xolair (omalizumab) shows superior efficacy and safety compared to multi-allergen oral immunotherapy in treating food ...

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for ...